Showing 3381-3390 of 7425 results for "".
- Industry Responds to COVID-19: Henry Schein Medical, PCA Skinhttps://practicaldermatology.com/news/industry-responds-to-covid-19-henry-schein-medical-pca-skin/2460344/Henry Schein Medical. Henry Schein Medical is making
- Rosacea Awareness Month Brings Focus to Common Skin Diseasehttps://practicaldermatology.com/news/rosacea-awareness-month-brings-focus-to-common-skin-disease/2460342/It’s Rosacea Awareness Month, and the National Rosacea Society (NRS) continues to educate the public on this potentially serious condition estimated to affect more than 16 million Americans. “Although the occurrence of rosacea has been well documented over the centuries, vir
- Lessons from Italy: Understanding and Recognizing Potential Skin Manifestations in COVID-19https://practicaldermatology.com/news/lessons-from-italy-understanding-and-recognizing-potential-skin-manifestations-in-covid-10-1/2460340/Italian dermatologists report that about 20 percent of COVID-19 patients may develop skin manifestations including red rashes. Their findings appear in Journal of the European Academy of Dermatology Venereology. The researchers looked at skin in 148 COVID-19 patients
- CSF Live Virtual Meeting to Assess SBA Loans: Tonighthttps://practicaldermatology.com/news/csf-live-virtual-meeting-to-access-sba-loans-tonight/2460334/As dermatology business owners’ heads are swimming trying to figure out the SBA loan to keep afloat during the COVID crisis, CSF, along with George Hruza, MD, immediate past-president of the AAD, and Greg Morganroth, MD, CEO and Founder of California Skin Institute, will discuss the ins-and
- Novartis Terminates Sale of Sandoz US Generic Oral Solids, Dermatology Portfolio to Aurobindo in Mutual Agreementhttps://practicaldermatology.com/news/novartis-terminates-sale-of-sandoz-us-generic-oral-solids-dermatology-portfolio-to-aurobindo-in-mutual-agreement/2460332/In a mutual agreement with Aurobindo Pharma USA Inc., Novartis has terminated the agreement to sell the Sandoz US generic oral solids and dermatology businesses to Aurobindo. This decision was taken as approval from the U.S. Federal Trade Commission for the transaction was not obtained within ant
- Industry Responds to COVID-19: E.T. Browne Drug Co., Columbia University Medical Center, RealSelfhttps://practicaldermatology.com/news/industry-responds-to-covid-19-def-leo-pharma-dermyoung-coty/2460329/E.T. Browne Drug Co. The manufacturer of Palmer' Cocoa Butter Formula and Coconut Oil Formula skin and hair care products is now producing medical-grade hand sanitizer to address widespread supply shortages in the wake of COVID-19. Initial production of the disinfectant sanit
- Positive Phase 3 Results Reported for Medimetriks and Otsuka's AD Drughttps://practicaldermatology.com/news/positive-phase-3-results-reported-for-medimetriks-and-otsukas-ad-drug-1/2460322/Medimetriks Pharmaceuticals, Inc. and Otsuka Pharmaceuticals Co. Ltd.’s MM36 (difamilast) performed well in two Phase 3 Japanese clinical trials in adult and pediatric atopic dermatitis (AD) patients. Difamilast is a novel topical, non-steroidal phosphodiesterase IV (PDE4) inhibit
- FDA Greenlights Pfizer’s Eucrisa for Children As Young As Three Months With ADhttps://practicaldermatology.com/news/fda-greenlights-pfizers-eucrisa-for-children-as-young-as-three-months-with-ad/2460321/The U.S. Food and Drug Administration (FDA) gave its nod to Pfizer’s Eucrisa ointment, 2%, for children as young as age 3 months with mild-to-moderate atopic dermatitis (AD). Eucrisa was previously approved for use in adults and children 2 years of age and older. It is the first a
- Destiny Pharma and MedPharm Complete Initial Phase of Development Projecthttps://practicaldermatology.com/news/destiny-pharma-and-medpharm-complete-initial-phase-of-development-project/2460318/Destiny Pharma and MedPharm have completed the initial phase of their project to develop new topical formulations of Destiny’s novel XF‐platform drugs. Further to forming the collaboration with MedPharm last year, the project has identified a range of new, stable XF formulations w
- Owing to the Advent of New Treatments, Melanoma Death Rates Drophttps://practicaldermatology.com/news/owing-to-the-advent-of-new-treatments-melanoma-death-rates-drop/2460312/Melanoma is killing the fewest Americans in decades, according to a study in the American Journal of Public Health. Death rates for metastatic melanoma among white Americans climbed 7.5 percent between 1986 and 2013, but then dropped by nearly 18 percent over the next thre